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wThe 34-member faculty for the Symposium in-
luded leaders of the major transplantation centers
rom around the globe. Attendees were from Japan,
ew Zealand, Australia, Singapore, France, the UK,
srael, Mexico, Colombia, Ecuador, Chile, Brazil,
enezuela, Argentina, Malaysia, India, Sweden, Italy,
pain, Slovak Republic, Taiwan, Saudi Arabia, the
AE, Kuwait, Greece, Netherlands, Canada, China,
ong Kong, Korea, Thailand and from across the
SA.
The program was divided into 8 sessions:
1) state of the art in cord blood transplantation,
2) optimal selection of stem cell products for he-
atopoietic cell transplantation, (3) umbilical cord
lood transplantation for patients with transfusion-
ependent thalassemia and sickle cell anemia,
4) quality issues in cord blood banking, (5) immune
econstitution following UCBT: graft-versus-leu-
emia, infectious complications, and adoptive immu-
otherapy, (6) transplantation of children, (7) devel-
pment of a national cord blood center, and (8) cord
lood cell biology, ex vivo expansion and regener-
tive medicine. The following comments empha-
ize signiﬁcant aspects of selected presentations.
urther details are provided in the abstracts that
ollow.
The Fourth Annual International Cord Blood Trans-
lantation Symposium was presented by the California
lood Bank Society and the Cord Blood Forum, and was
artially supported by unrestricted educational grants from
temCyte and the National Marrow Donor Program
NMDP). The Symposium was also partially ﬁnancially
upported by a contract between the Health Resources and
ervices Administration (HRSA), US Department of
ealth and Human Services, and the California Blood
ank Society. Any opinions, ﬁndings, conclusions or recom-
endations expressed or presented at this conference or those
f the presenters and do not necessarily reﬂect the views of
he US Government. e
206ESSION 1. STATE OF THE ART IN CORD
LOOD TRANSPLANTATION
ession 1A. Review lecture: umbilical cord blood
ransplantation: the state of the art
Dr. John Wagner reviewed the history and current
tate of knowledge with regard to umbilical cord
lood transplantation (UCBT). Based on an analysis
f factors impacting leukemia free survival, data re-
orted to the CIBMTR and New York Blood Center
ould suggest that the optimal donor source is an
LA matched unrelated UCB unit with all other
onor sources being virtually identical (ie, HLA
atched marrow, HLA 1 antigen mismatched mar-
ow, HLA 1 or 2 antigen mismatched UCB). This
nding supports the use of HLA 1-2 antigen mis-
atched UCB particularly for the estimated 15,000
atients each year who cannot locate a suitably HLA
atched unrelated adult volunteer donor. However,
here remains great impetus to overcome the obstacles
f marrow donor searches, namely prolonged search
ime (several months), lack of HLA matched donors
articularly for ethnic and racial minority recipients,
nd high risk of transplant-related mortality (TRM).
ertain properties of UCB, especially immune prop-
rties and rapid availability, make it interesting to
xplore. Cell dose, however, is clearly the limiting
eature of UCB transplantation to date. Therefore,
reat emphasis has been made on overcoming this 1
ajor obstacle. Multiple strategies have been pro-
osed to address the cell dose limitation: namely, ex
ivo expansion culture, co-infusion of haploidentical
eripheral blood, use of multiple UCB units, co-infu-
ion of mesenchymal stem cells, intra-bone marrow
njection and methods for enhancing the homing of
CB hematopoietic stem cells and progenitors to the
arrow microenvironment. In addition, novel strate-
ies for reducing regimen related mortality (RRM) as
ell as enhancing the graft-versus-leukemia leukemia
ffect of the UCB graft have been explored. In antic-
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Summary of IUCBT Symposium 1207pation of the various presentations over the confer-
nce that would be discussing the most recent gener-
tion of UCB studies, Dr. Wagner reviewed published
utcomes with conventional myeloablation and single
CB transplantation.
The results of the NHLBI sponsored COBLT
rial as well as published results from the University of
innesota (n  102, from 1994-2001) were used to
ighlight a “standard” by which more recent trials
ight be compared. While initial studies in the mid
990s used 1  107 TNC/kg as the minimum accept-
ble cell dose, it has now been shown that a dose of
.5  107 kg is the lower limit. In the University of
innesota analysis, CD34 cell dose had a deﬁnite
ffect on neutrophil recovery and survival with poorer
esults in recipients of CD34 doses 1.7  105
D34/kg. Because large intra-laboratory variation oc-
urs between labs, the general use of CD34 cell
numeration as a criterion for selecting UCB units for
ransplantation is prevented. Multiple regression anal-
ses further indicate that HLA match, CD34 cell
ose, and grade II-IV acute GVHD are signiﬁcant
actors associated with survival.
In the COBLT study, consisting primarily of pe-
iatric patients, HLA match, and TNC and CD34
ell doses were not factors associated with overall
urvival. Factors that did inﬂuence survival were pri-
ary disease, recipient CMV status, recipient gender
male recipients did better), donor race (Caucasian
onors were better), and performance status. Higher
urvival rates were observed in recipients of high res-
lution HLA matched UCB units, although the
trength of this conclusion was limited by a small
umber of patients.
A CIBMTR retrospective analysis demonstrated
owest risk of treatment related mortality in recipients
f 6/6 HLA matched units whereas relapse was lowest
n recipients of an HLA 2 antigen mismatched unit.
hese ﬁndings explain the lack of effect of HLA and
ell dose on leukemia free survival (in that higher
RM is countered by reduced risk of relapse in pa-
ients transplanted with HLA 2 antigen mismatched
arrow).
Studies in adults, notably those of Rocha et al and
aughlin et al (NEJM, 2004) demonstrate similar sur-
ival between recipients of at least 1 antigen mis-
atched BMT and UCBT, but the results overall are
oor regardless of donor. While increasing the CB
nventory may increase the likelihood of ﬁnding a
losely HLA matched UCB donor, the greatest focus
eeds to be on ﬁnding ways for increasing the “func-
ional” cell dose. Together, these strategies should
ave a profound positive impact on results in adults.
As outlined in the Program, there are numerous
pproaches that can be explored for enhancing the
VL/GVT of UCB. Strategies include: multi-unit
CBT, co-infusion of UCB derived NK cells, or wo-infusion of genetically modiﬁed UCB derived T
ells targeting leukemic populations. Also, data from
he NYBC suggest that an effective approach for im-
roving engraftment is the use of ﬂudarabine in the
reparative regimen. Results with ex vivo expansion
ulture, novel growth factors, multiple CB units, in-
ra-bone marrow injection, and non-myeloablative
egimens will be discussed during the Symposium.
Other new developments in the ﬁeld include con-
ideration of novel applications including the use of
ffector cell therapy and expansion of the use of UCB
o new diseases. Finally, major efforts to increase the
.S. UCB inventory are being implemented, as a
esult of the Stem Cell Therapeutic and Research Act of
005.
ession 1B. Reduced-intensity pre-transplantation
onditioning regimens
Dr. Vanderson Rocha discussed reduced-intensity
onditioning for single unrelated cord blood trans-
lants for adults with hematological malignancies.
his was an Eurocord-Netcord group analysis of 65
atients with a median age of 47 years (16-76) and
edian weight of 60 kg (40-110 kg). Sixty-three per-
ent of patients were CMV and 39% had a previous
utologous transplant. This was a very high risk group
ith 49% having advanced disease. The conditioning
egimens generally included ﬂudarabine, with the most
ommon regimen being ﬂudarabineendoxanTBI
2 Gy). Twenty-six percent of patients received anti-T-
ell antibodies and 87% received hematopoietic growth
actors (day 8); GVHD prophylaxis most commonly
55%) consisted of CsA and MMF. The median TNC
ollected was 3.7  107/kg; the median TNC infused
as 2.4  107/kg; the median cell loss after thawing
as 15%. Chimerism analysis was available in 71% of
he patients at 3 months and was full donor in 67%,
ixed chimerism in 9% and autologous reconstitution
n 24%. Neutrophil recovery was 87  7% of the 26
atients who received the FluEndTBI condition-
ng regimen and was 65  10% for patients receiving
ther regimens. Grade II aGVHD was found in 13%,
rade III in 7% and grade IV in 7%; the TRM was
5  7% overall, 50  9% in acute leukemia, 30 
5% in lymphomas and 27  16% for other diag-
oses. The TRM at 1 year for those receiving 2.4 
07 TNC/kg was 53  9% and that for those receiv-
ng 2.4  107TNC/kg was 39  10%. For patients
eceiving FluEndTBI the TRM at 1 year was 24
0% and that for those receiving other conditioning
egimens was 60  9% (P  0.001). DFS at 1 year for
ymphomas was 50 9%, for leukemias was 27 7%,
nd for other diagnoses was 0. When the number of
LA mismatches was 0-1, DFS at 1 year was 42 
2% (n 28), for 2 disparities DFS was 27 9% (n
4) and for 3-4 disparities DFS was 0 (n  9). DFS
as 43  11% for those receiving FluEndTBI
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Summary of IUCBT Symposium1208n  26), and was 16  7% for patients receiving
ther conditioning regimens (n 38) (P 0.005). For
atients receiving 2.4  107 TNC/kg the DFS was
1  12% and for patients receiving 2.4 
07TNC/kg the DFS was 14  8% (P  0.05). The
uthors concluded that the results of single unrelated
CBT with reduced intensity conditioning regimens
re encouraging and that cell dose and HLA remain
mportant factors in this setting. The type of condi-
ioning (FluEndTBI) seems to be associated with
ecreased TRM and better DFS, but a multivariate
nalysis with a higher number of patients is needed.
Dr. Shigesaburo Miyakoshi presented several sets of
ata regarding reduced-intensity unrelated cord blood
ransplantation (RI-UCBT) for patients with hemato-
ogic malignancies. First he summarized results of a
tudy of 97 adult patients who received a conditioning
egimen of ﬂudarabine, melphalan and TBI (4Gy).
he overall survival (OS) for standard risk patients
n  22) was 67% (95% CI, 47-87) and for high risk
atients (n  81) was 31% (95% CI, 20-43). A second
tudy of ALL in adults involved 22 cases. The OS was
bout 60% and disease-free survival (DFS) about 48%
ith better survival noted for patients who were trans-
lanted in complete remission. In a study of 34 cases
f relapsed and refractory malignant lymphomas, the
S and DFS at 2 years was 24% and 16%, respec-
ively. For chemo-sensitive patients the OS was 73%,
hereas for chemo-refractory patients, it was 13%.
eaths from transplant related mortality (TRM) were
igher than for relapse. A further study compared the
utcomes of related PBSCT, UBMT, and UCBT
ith reduced intensity regimens. Neutrophil and
latelet engraftment were slower with RI-UCBT than
ith RI-PBSCT, but the incidence of acute GVHD,
RM and OS were similar among these 3 stem cell
ources with reduced intensity regimens. However,
elapse rate might be higher than others over 100 days
fter RI-UCBT. The most important problem after
I-UCBT is high TRM so that transplant physicians
hould consider means to decrease TRM.
Dr. Prakash Satwani discussed reduced-intensity
llogeneic cord blood hematopoietic cell transplanta-
ion in pediatric patients with malignant and non-
alignant diseases. Previously published data indicate
hat RI AlloSCT results in reduced grade III/IV neu-
ropenia and thrombocytopenia, decreased transfusion
equirements, decreased bacterial infections and re-
uced grade II acute GVHD. A study of 22 patients
or whom the RI conditioning was ﬂudarabine-based
150-180 mg/m2) with busulfan and rabbit ATG
n  17) or ﬂudarabine  cyclophosphamide 
toposideATG (n 5). Seventeen patients had malig-
ant disease whereas 5 had non-malignant diseases. The
edian nucleated cell dose was 3.8  107/kg. The
robability of 3-year OS in all patients was 63% and
or standard-risk malignancy patients was 90%. 5owever, the 1-year OS in poor-risk malignancy
atients was 21% and 2 year survival was 0. Thus,
I AlloCBHCT is a promising transplant option in
hildren and adolescents, particularly in those pa-
ients with malignancies that are not far advanced,
nd should be offered to pediatric patients whose
ondition at the time of transplantation puts them
t a high risk of toxicity from myeloablative trans-
lantation. It appears to be contraindicated in ma-
ignant conditions with progressive disease and/or
igh tumor burden.
ession 1C. Review lecture: double umbilical cord
lood transplants (UCBT) with myeloablative or
educed-intensity conditioning regimens
Dr. Scott Baker pointed out that the rate of hema-
opoietic recovery is cell dose dependent as is the
ncidence of engraftment, TRM and survival; also, the
egative impact of HLA mismatch can be partially
eversed by cell dose. In a study at the University of
innesota, ﬁfty patients received myeloablative dou-
le UCBT and the results were compared with 21
atients who received a single UCBT. In the double
CBT the units were HLA matched at least at the 4/6
evel with the patient and with each other; the com-
ined cell dose was 3.5  107 TNC/kg. There was no
ifference in cell dose between the 2 groups. Sustained
onor engraftment was seen in 88% of doubles com-
ared to 95% in singles (P  0.08) at a median of 24
ays. Grade II-IV aGVHD was higher in doubles
66%) compared to singles (38%) (P 0.02) but grade
II-IV aGVHD was similar (20% in doubles vs 14% in
ingles; P 0.51). TRM was similar in the two groups
doubles 22% vs singles 19%) as was DFS (59% dou-
les vs 56% singles) and OS (63% doubles vs 56%
ingles) singles. The conclusion reached was that the
o-infusion of 2 partially HLA matched UCB units in
he myeloablative setting offers the opportunity of
afer and more successful UCBT for larger patients
nd provides a high incidence of engraftment, low
RM, and potentially a lower risk of relapse. In an-
ther study, 95 patients received a non-myeloablative
ouble UCBT and the results were compared with 17
atients receiving a single UCBT. Results were com-
arable to 5 published series by other investigators.
ustained neutrophil engraftment was 85% with dou-
les vs 94% with singles (P  0.08); ATG was shown
o improve engraftment for patients lacking recent
hemotherapy, but was associated with increased risk
f EBV viremia or PTLD. TRM was 15% in doubles
s 29% in singles (P 0.17); OS at 3 years was 45% for
oubles and 40% for singles (P  0.30). Multivariate
nalysis indicated that independent predictors of inferior
urvival were lack of chemotherapy or prior auto-trans-
lant within the previous 3 months, grade III-IV
GVHD, and presence of co-morbidity (Karnofsky
0-60%, major organ dysfunction, or major prior life-
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Summary of IUCBT Symposium 1209hreatening infection). The conclusions were that
MA UCBT is associated with a high probability of
himerism, a low incidence of TRM despite older age,
low risk of aGVHD despite HLA mismatch and
lder age, and promising DFS and OS results.
ession 1D. Double cord blood transplants
Dr. Karen Ballen discussed double cord blood
ransplantation using a reduced intensity chemother-
py only conditioning regimen. Twenty-one adult pa-
ients with good risk hematologic malignancies were
ransplanted with 2 cord blood units with a total pre-
ryopreservation dose of 3.7  107 TNC/kg. The
onditioning regimen consisted of ﬂudarabine, mel-
halan, and rabbit ATG. ANC 500 was reached at a
edian of 20 days, and median days to platelet
20,000 was 41 days. Forty percent had grade II-IV
GVHD but no patient had grade IV aGVHD and
here were no deaths from aGVHD; 5 patients had
GVHD which was extensive in 2 and caused death in
. The 100-day TRM was only 14%, OS at 1 year was
1%, and DFS at 1 year was 66%. Infection was a
igniﬁcant problem and was treated aggressively. New
nformation was presented including the fact that
arathyroid hormone post-transplant appears to im-
rove survival in a mouse competitive transplant
odel. The conclusions reached were that double
CBT using a reduced intensity conditioning regi-
en provides an alternative stem source for patients
ithout matched related or unrelated adult donors,
nd achieves engraftment in adults. Emphasis in con-
inuing studies should be on improving immune re-
onstitution.
Dr. Michael Verneris discussed the risk of relapse
fter UCBT in patients with acute leukemia with
mphasis on a comparison of outcomes following sin-
le vs double unit grafts. A retrospective study was
erformed comparing the outcomes in 109 patients;
7 patients received a single and 42 patients received
double UCBT. The patients had AML or ALL and
ll received myeloablative conditioning. Two different
onditioning regimes were used: regimen A consisted
f cyclophosphamide, TBI, and ATG, followed by
SA/methylprednisolone immunosuppression (n 
3), and regimen B consisted of cyclophosphamide,
udarabine, TBI, and CSA/MMF immunosuppres-
ion (n  43). Potential risk factors for relapse that
ere evaluated included: age, gender, recipient CMV
ero-status, diagnosis, disease risk, HLA disparity,
onditioning regimen, and TNC dose of the unit
esponsible for sustained engraftment. Outcomes re-
iewed were neutrophil recovery, TRM, acute and
hronic GVHD, relapse and overall survival. In Cox
egression analysis 2 factors were associated with
ower relapse risk: disease risk (CR1/CR2 vs CR3/
EL; RR, 0.32; P  0.02) and transplantation of two (CB units (RR, 0.3; P  0.03). The diagnosis, UCB
raft cell dose, and presence of aGVHD had no de-
onstrable impact. Patients who received regimen B
n CR1/2 showed a signiﬁcantly lower risk of relapse
ith 2 UCB units compared to 1 unit (11% vs 54%,
 0.01). This is the ﬁrst report suggesting that
ouble unit UCB grafts may be associated with re-
uced relapse risk in acute leukemia.
Dr. Michael Creer discussed a retrospective case
ontrol study which compared single cord transplants
SCT) vs dual cord transplants (DCT) in adults with
cute leukemia undergoing myeloablative transplant
onditioning. Twenty DCT cases were compared
ith 20 comparably matched SCT recipients with the
argest TNC dose. Patients were matched for age, sex,
iagnosis, disease status, ethnicity and body weight
xcluding patients with graft failure or previous trans-
lants. The administered TNC dose for DCT (3.7 
07 TNC/kg) was nearly 2-fold greater than SCT
1.9  107 TNC/kg). Overall survival (OS) at 12
onths was 18% for SCT and 72% for DCT (P 
.0001) with median duration of follow-up of 18
onths for both SCT and DCT. Although the TNC
ose was approximately 2-fold greater in DCT recip-
ents, the difference in OS for DCT recipients is
reater than that expected on the basis of increased
ell dose alone. In the ﬁrst 100 days post-transplant,
nfection rates for SCT and DCT were similar; how-
ver, infection was the primary cause of death at 100
ays for SCT (9/20), whereas for DCT there were no
nfection-related deaths at 100 days post-transplant.
onclusions reached were that OS of adult patients
eceiving DCT is signiﬁcantly greater than that fol-
owing SCT. There were no reported deaths from
nfection in DCT recipients in the ﬁrst 100 days
ost-transplant although the frequency of infection
as similar to that in recipients of SCT. The TNC
ose was related to infection frequency and mortality
rom infection in SCT recipients, but infection fre-
uency was not related to cell dose in DCT recipients.
ccordingly, earlier recovery of neutrophil production
nd other potential beneﬁts arising from infusion of cord
lood units from 2 different donors may contribute to
educed early transplant-related mortality that is inde-
endent of increased TNC dose in DCT recipients.
ESSION 2. OPTIMAL SELECTION OF STEM
ELL PRODUCTS FOR HEMATOPOIETIC
ELL TRANSPLANTATION
Dr. Dennis Confer presented a talk entitled “HLA
atching for transplantation: lessons from bone mar-
ow.” Available HLA loci are HLA-A, B, C, DRB1;
RB3, 4 and 5; HLA-DQA and B; and HLA-DPA
nd B. One may type at different levels of resolution: low
broad “antigens”), intermediate (split “antigens”), and
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Summary of IUCBT Symposium1210igh (“allele level” or sequence level). Questions that
rise about HLA typing for hematopoietic cell trans-
lantation (HCT) include: How many loci should I
ype? How many loci should I match? What level of
esolution should be used? What about DQ and DP?
re some loci more important than others? Answers
or some of these questions are available for bone
arrow transplantation, but much less information is
vailable regarding cord blood transplantation. An
nalysis by the NMDP of overall survival (OS) follow-
ng 3559 bone marrow transplants indicated that a
ismatch at the antigen level for HLA-A, -B, -C and
RB1 was associated with a statistically signiﬁcant
ncreased risk for mortality as was high resolution
ismatch for HLA-A. An analysis focusing an allele
ismatching indicated that mismatches at A, B, C or
R reduced OS but mismatch at DQ or DP had no
emonstrable effect. Conclusions about HLA typing
or bone marrow transplantation were: 8 of 8 allele-
evel matching at HLA-A, -B, -C and -DRB1 is pre-
erred; when a single mismatch is present, antigen
ismatches fare worse than allele mismatches; the
ole of HLA-DQ is uncertain; and the weighting of
ultiple mismatches is unknown.
Dr. Juliet Barker discussed an analysis of 607 um-
ilical cord blood transplants facilitated by the New
ork Blood Center for the treatment of acute leuke-
ia or myelodysplasia. With the recognition that cell
ose (TNC) is a critical determinant of hematopoietic
ecovery, and with the use of new conditioning regi-
ens and the use of double unit grafts, engraftment is
o longer a major limitation to successful UCBT for
any patients. However, transplant related mortality
TRM) remains a barrier to UCBT. Therefore, the
im of the present study was to analyze the impact of
NC dose and HLA match upon post-engraftment
RM (days 30-180) in engrafting patients. Results
ndicated that while low cell dose 2.5  107
NC/kg was associated with day 30-180 TRM, in-
reased cell dose above a dose of 2.5  107 TNC/kg
as not beneﬁcial. In contrast, HLA-mismatch was
ndependently predictive of TRM at all levels of
atch. The group was then divided into those patients
ith grade 2-4 aGVHD and those without GVHD.
nalysis of each of these groups revealed that the
dverse impact of HLA-mismatch upon TRM was
ost pronounced in the absence of aGVHD (grade
-1), with 63% of the deaths in this group being due
o infection. Conclusions reached were that cell dose
s a critical determinant of engraftment and TRM, but
hat in engrafting patients, cell dose 2.5  107
NC/kg had no impact on day 30-180 TRM. In
ontrast, HLA-mismatch was an independent risk fac-
or for post-engraftment TRM at all levels of match
ven in the absence of signiﬁcant aGVHD, possibly
ue to an adverse impact of mismatch on immune
econstitution. An important implication of these data ms that improved UCBT outcomes will depend on the
bility to obtain units of both sufﬁcient size and
atch, and that this will require an increase in the
lobal UCB inventory.
Dr. Priya Kumar presented data regarding alloge-
eic hematopoietic stem cell transplantation in the
reatment of acute lymphocytic leukemia (ALL). In a
ingle center study, outcomes were compared among
different donor sources: HLA-matched related do-
or (MRD) (n  85), HLA-matched unrelated donor
URD:M) (n  15), HLA-mismatched unrelated do-
or (URD:MM) (n  14), and HLA-0-2 mismatched
mbilical cord blood (UCB) (n  12). The patients
nderwent myeloablative conditioning (a cyclophos-
hamide 120 mg/kg and total body irradiation 1320-
375 cGy based regimen in 92%) followed by alloge-
eic HSCT. As a consequence of low transplant
elated mortality (TRM), overall survival (OS) and
eukemia free survival (LFS) were superior after UCB
ransplants. In multiple regression analysis, 5 indepen-
ent risk factors were signiﬁcantly associated with
oorer OS: use of URD:M and URD:MM, CR3 at
SCT, WBC 30  109/L, cytomegalovirus (CMV)
eropositive recipient and donor, and 2 induction
egimens to achieve initial CR. GVHD was associated
ith improved LFS, suggesting a signiﬁcant GVL
ffect across all donor sources. In conclusion, these
esults support the use of UCB as an acceptable donor
ource for adult ALL with results comparable to
RD, but ﬁndings must be conﬁrmed using studies
ith larger numbers of patients.
Dr. Eliane Gluckman presented the results of a
tudy of the impact of the number and type of HLA
ncompatibilities and cell dose on outcomes of unre-
ated cord blood transplants for patients with malig-
ant and non-malignant disorders. One thousand pa-
ients with hematological malignancies were analyzed.
he results indicated that cell dose is the most impor-
ant factor for engraftment and TRM. A minimum of
 107 nucleated cells/kg at collection and 2 
07/kg at infusion must be obtained. HLA mismatches
ncrease the risk of engraftment delays, TRM and
GVHD, but decreases the risk of relapse resulting in
n absence of the role of HLA mismatches for sur-
ival. Increasing cell dose partially abrogates the in-
uence of HLA mismatches.
In 268 patients with non-malignant diseases, re-
uirements for cell dose and HLA matching were
ifferent compared to malignant diseases. In non-
alignant diseases, cell dose is higher at 4.9  107/kg
t collection and 3.5  107/kg at infusion. HLA mis-
atches play a major role for engraftment, survival
nd GVH. It is partially abrogated by increasing cell
ose. Two HLA DRB1 mismatches resulted in an
dverse outcome.
Conclusions were that HLA mismatches play a
ajor role for engraftment and survival in non-malig-
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Summary of IUCBT Symposium 1211ant diseases, while in malignant disease mis-
atches have a beneﬁcial role for preventing leuke-
ic relapse resulting in an absence of effect on LFS.
LA mismatches can be partially overcome by increas-
ng cell dose, and matching for class II is better than for
lass I.
Dr. Dennis Confer moderated a panel discussion (Drs.
arker, Gluckman, Wagner, Kurtzberg, and Stevens) with
he goal of developing a consensus statement on the
ptimal selection criteria for cord blood stem cell
roducts. The panelists agreed that when the cell dose
s marginal, HLA match becomes more critical. With
HLA 5/6 match, a cell dose above 2.5 to 3.0  107
NC is adequate above which there is no additional
eneﬁt. For a HLA 4/6 match, a minimal dose2.5
07 TNC/kg may be adequate, although a preferable
umber might be as high as 4.0  107 TNC/kg, and
here is a continuum of effectiveness with increasing
ell doses. A somewhat lower cell dose may be ade-
uate for 6/6 matches.
When TNC and CD34 cell dose values seem
iscrepant, there is no way to resolve the problem and
suggestion was to not use such units. In regard to
D34 cell dose, the panelists agreed that CD34
ell dose probably correlates better with transplant
utcome than TNC, but the reality is that the present
tatus of CD34 testing is such that one cannot com-
are results from one laboratory to another. Thus,
xcept in laboratories that develop their own data with
method for measurement, CD34 cell dose cannot
e used to select units.
ESSION 3. UMBILICAL CORD BLOOD
RANSPLANTATION FOR TRANSFUSION-DEPENDENT
HALASSEMIA AND SICKLE CELL ANEMIA
Review lecture. Dr. Mark Walters pointed out that
ore than 2500 hematopoietic cell transplants (HCT)
ave been done for -thalassemia major, primarily
ith HLA-identical sibling marrow donors. Recent
ata indicate that in Lucarelli class 1 and class 2
atients transplanted with marrow from sibling do-
ors, the thalassemia-free survival rate is 87% and
4%, respectively. For class 3 patients 17 years of
ge who were treated with a conditioning regimen
roviding more intensive chemosuppression, the DFS
as 85% and OS was 93%. Unrelated BMT in chil-
ren with class 1 or 2 thalassemia have an OS of 92%
nd DFS of 82%, results that are similar to those
btained with sibling BMT. Also of note is that post-
MT phlebotomy has been shown to result in im-
rovement in liver ﬁbrosis and iron overload. In sickle
ell disease (SCD), studies of survival of patients man-
ged only with supportive care indicate a mean age of
eath in males of 42 years and in females of 48 years,
30-year decrement compared to normal. Following eMT using sibling donors, the OS is 93% and the
FS is 85%. Importantly, patients who have been
ured of SCD with BMT have no painful crises, no
pisodes of acute chest syndrome, no episodes of
plenic or hepatic sequestration, no need for RBC
ransfusions and do not develop stroke, TIA or hem-
rrhagic CNS events. A sibling donor program estab-
ished in the late 1990s has led to the transplantation
f 28 patients with umbilical cord blood (UCB) units
or SCD or thalassemia (a minority of the transplants
as supplemented with bone marrow from the sib-
ing). With about an 8-year follow-up, the OS is 89%
nd the DFS is 86%. Further, the GVHD rate is low
nd no patient has died of GVHD, whereas this is the
eading cause of death after BMT. Conclusions were
hat HCT for SCD and thalassemia is curative in the
ajority of children who receive this treatment and
hat UCB transplantation using sibling-donors pro-
uces results similar to those of BMT. The risk/
eneﬁt considerations favor HCT in the long term for
CD and thalassemia, and high-risk patients with
ickle cell anemia may also beneﬁt in the short-term.
Dr. Tang-Her Jaing discussed unrelated umbilical
ord blood transplantation (UCBT) for hemoglobi-
opathies. Between July 1991 and April 2006, 39
nrelated UCBTs were performed in 38 pediatric
atients with hemoglobinopathies (36 transfusion-de-
endent thalassemia and 2 sickle cell disease) using 45
mbilical cord blood units (6 double cords and 1
e-transplant) after myeloablative therapy at the au-
hors’ institutions and 11 other centers using mostly
lasma depleted cord blood units (36/45) that were
ot washed after thawing (38/45). Eighteen patients
ere Pesaro class 1, 5 class 2, and 1 class 3, with 12
tatus unknown. The median age of patients was 6
ears (range, 0.3-20 years) with a median weight of 19
g (range, 8-76 kg). The cumulative incidence of un-
djusted ANC 500 with donor chimerism and platelet
0,000 engraftment was achieved in 81  7% and 79 
% of the cases, respectively. Median times to ANC
00 engraftment, and platelet 20,000 engraftment
ere 17 days (range, 11-33 days) and 40 days (range,
6-135 days) after transplantation, respectively.
Eight patients died with 2 early deaths prior to day
0 and 1 traumatic accident. All remaining 30 patients
re alive (25 are thalassemia-free and 5 have autolo-
ous recovery) for a 2-year OS of 77  7% and DFS
f 65  5%, with a mean and median follow up time
f 392 and 257 days, respectively (range, 7-1760 days).
n analysis was undertaken to compare experienced
enters (5 cases) with less experienced centers, as
ell as to compare results with units that were washed
ost-thaw versus units that were not washed. The
verall survival and disease free survival at experienced
enters that did not perform post-thaw wash of the CB
nit were 87  7% and 77  9%, respectively. At
xperienced centers that do not practice post-thaw
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Summary of IUCBT Symposium1212ash, outstanding results were obtained with plasma
epleted CBU - ANC 500 93  7%, platelet 20,000
1  8%, and 2-year DFS 86  9%. When cell dose
nd other factors are optimal, unrelated CBT is a
romising approach for curative therapy of transfu-
ion-dependent thalassemia major.
Dr. Shalini Shenoy presented data regarding re-
uced intensity conditioning in stem cell transplants
erformed for non-malignant disorders of childhood.
he conditioning regimen consisted of campath-1H
days 	21 to 	19), ﬂudarabine (days 	8 to 	4) and
elphalan (day 	3); GVHD prophylaxis consisted of
SP/tacrolimus, methyl prednisone, and a short
ourse of MTX. Supportive care emphasized infection
urveillance and prophylaxis, and disease speciﬁc care.
iagnoses included metabolic disorders (n  13), im-
une function disorders (n  25), bone marrow fail-
re (n  7), hemoglobinopathy (n  6) and Evans
yndrome (n  1). Twenty-six patients received an
nrelated BMT or PBSCT, 11 an unrelated UCBT,
nd 15 a related donor BMT (HLA-matched). Graft
ejection occurred in 5% of patients; myeloid engraft-
ent was achieved at a median of 13 days (range,
0-36 days) and platelet engraftment (50,000) at a
edian of 26 days (range, 12-82 days). OS was 93%
nd 83% and event-free survival was 86% and 73% in
elated and unrelated transplants, respectively. Acute
VHD grade 2 occurred in 15% and cGVHD in
1%. Infectious complications occurred during the
rst 6 months. Of the 6 patients with hemoglobinop-
thies, 4 achieved 100% donor chimerism, none devel-
ped acute GVHD, and 1 patient developed cGVHD of
he skin; Lansky scores were 90%-100%. Two patients
ith sickle cell disease who received lower doses of
elphalan failed to achieve donor chimerism and had
utologous recovery. They are alive with Lansky
cores of 100%. Conclusions were that the condition-
ng regimen was well tolerated, successful engraftment
ccurred with BM, PB, and UCB, and that the rates of
RM and GVHD were acceptable.
ESSION 4. QUALITY ISSUES IN CORD
LOOD BANKING
Dr. Emer Clarke discussed standardization of CFU
ssays for cord blood products. A program was devel-
ped to assess variability in fresh CB samples. A stan-
ardized protocol was provided and participants mea-
ured TNC, viability and plated a speciﬁed number of
iable cells; assays for BFU-E, CFU-GM, CFU-
EMM and total CFC were performed on day 14.
esults on fresh CB indicated the following coefﬁ-
ients of variation (CVs): TNC 6.1%, viability 3.2%,
nd viable TNC 6.4%. Results for colony assays were
ore variable with CVs as follows: BFU-E 40.6%,
FU-GM 65% and total CFC 34.4%. On frozen CB tamples CVs were: TNC 16.5%, viability 35.7% and
iable TNC 40.9%. In 1 survey 17 of 41 sites reported
o growth in their colony assays and the investigation
f the lack of growth is presently under investigation.
onclusions were that cell number and viability as-
essment from fresh cord blood samples was excellent;
ariability in the recognition of colonies is increased
ith RBC background; and the variability in cell and
iability assessment in frozen samples was signiﬁcantly
reater than in fresh samples.
Dr. Cladd Stevens discussed HLA matching for
ord blood transplantation with emphasis on an em-
irical analysis of the chance of ﬁnding an HLA
atched CBU in the NY Blood Center cord blood
ank. The analysis included 14,378 search requests for
atients with high resolution DRB1 typing using a CB
nventory of 25,917 CBUs with high resolution DRB1
yping. The ethnic distribution of patients was 4.4%
sian, 13.3% African-American, 15% Hispanic and
7.3% Caucasian. Among CBU donors, 6.6% were
sian, 16.4% were African-American, 17% were His-
anic, 50.4% were Caucasian and 9.6% were mixed.
he chances of 1 matched CBU were as follows:
Ethnic Group 2 MM 1 MM 0 MM
sian 98.9% 55.7% 6.9%
frican-American 98.8% 48.4% 2.4%
ispanic 98.9% 59.7% 8.3%
aucasian 99.5% 70.6% 13.1%
ll patients 99.3% 65.0% 10.6%
The effect of inventory size on chance of ﬁnding
1 5/6 or 6/6 CBU match for Caucasians is as follows:
Inventory Size Probability of Finding 5/6 or 6/6 Matched Unit
5000 36.0%
10,000 47.9%
15,000 55.3%
20,772 61.2%
25,917 65.2%
Other data indicated that patients with a 6/6
atch had a lower rate of relapse than those with
LA mismatches (in contrast to some data presented
y others). Among patients with 0 HLA mismatches,
RM was not affected by increasing cell doses. When
or 3 HLA mismatches were present, the TRM was
ncreased above the level found with 0 and 1 HLA
ismatch. The interaction of HLA mismatch and
NC dose was important: compared to transplants
ith 1 mismatch and a high cell dose (5.0  107
NC/kg), TRM was progressively increased when
here were 2 mismatches but high cell dose, 1 mis-
atch with a low cell dose and 2 mismatches with a
ow cell dose.
Dr. Robert Chow presented data on the outcome of
ord blood transplantation (CBT) using 2 approaches
o maximize cord blood (CB) cell dose: depletion of
p
p
c
p
f
P


m
r
k
i
t
j
m
w
f
d
4
e
b
(
c
1
r
t
a
t
C
d
o
4
p
5
p
r
R
a
y
0
5
P
C
c
n
r
C
g
t
1
b
p
g
(
w
t
p
f
i
s
l
a
f
s
p
f
i
v
o
1
t
o
a
p
c
p
b
t

i
S
U
C
o
n
c
a
a
i
I
l
(
r
t
c
G
a
t
t
G
r
r
t
t
r
t
Summary of IUCBT Symposium 1213lasma (PD) but not of red blood cells during CB
rocessing, and no post-thaw washing (NW). Out-
omes of all CBTs using 237 PD CB units in 215
atients with audited engraftment and/or survival data
rom 2 cord blood banks up to 3/2006 were analyzed.
atient’s median age was 9 years (0.3-59) with 33%
16 years; median weight 30 kg (4.5-112) with 35%
50kg; median number of HLA ABDR matches 4.0;
edian TNC dose 5.3  107/kg; transplant center
eported median post-thaw TNC dose of 4.4  107/
g; median CD34 dose 1.8  105/kg; malignant
ndications 70%; transplants outside US 39%; double
ransplant 27%; and non-myeloablative 16%. Unad-
usted ANC 500, platelet 20,000 and 50,000 engraft-
ent (all deaths prior to engraftment as graft failures)
ere 88  3%, 82  4% & 76  4%. With a median
ollow-up of 325 days, 1-year overall survival (OS) and
isease-free survival (DFS) were 59  4% and 54 
%, respectively. Stratiﬁcation analysis showed worse
ngraftment and survival outcome at cord blood
ank’s CD34 cell dose below 0.7  105/kg.
There were 113 washed (W) and 95 non-washed
NW) PD CBTs. No signiﬁcant adverse events oc-
urred when the recommended DMSO threshold of
g per kg recipient weight was not exceeded. TNC
ecovery after thawing as reported by transplant cen-
ers was higher for NW (median, 89% vs 75%). Un-
djusted engraftment rates were higher and median
ime to engraftment was earlier for NW than W PD
B: 92 3% and 20 days for NW vs 88 3% and 24
ays for W for ANC500 (with RR of W at 1, Cox RR
f NW for engraftment 1.46, P  0.02), 89  5% and
4 days for NW vs 79  5% and 58 days for W for
latelet 20K (Cox RR 1.79, P  0.002), 88  5% and
7 days for NW vs 74  5% and 75 days for W for
latelet 50,000 (Cox RR 1.73, P  0.006). Relapse
ates were 16 4% for NW and 28 5% for W (Cox
R 0.55, P  0.09), with TRM at 26  5% for NW
nd 33  5% for W (Cox RR 0.92, P  0.75). One-
ear OS was 63  5% vs 54  5% (Cox RR for death
.87, P  0.54), and 1-year DFS was 62  5% vs 48 
% for NW and W (Cox RR for relapse or death 0.77,
 0.23), respectively.
The authors concluded that outcomes using PD
BT compare favorably to published data of out-
omes using RBC depleted CBT. There appears to be
o clear beneﬁt for post-thaw washing of PD CB, and
esults in this study indicated better results with NW
B units with respect to neutrophil and platelet en-
raftment rate and speed to engraftment; favorable
rends were noted regarding TRM, relapse rate,
-year OS and DFS.
Dr. Michael Creer discussed a comparison of cord
lood product thawing methods on cell recovery and
rogenitor integrity. A study was designed to investi-
ate the effects of an albumin reconstitution approach
AR) (albumin dilution, no wash) to conventional bashing (CW) following thawing of the frozen hema-
opoietic progenitor cells utilizing the following end-
oints: cell recovery and viability, progenitor cell
unction, and transplant outcome. Results of the study
ndicated that following AR, the stability of the recon-
tituted HPC population is as good as that seen fol-
owing CW, TNC recovery is signiﬁcantly improved
nd the procedure is faster and much easier to per-
orm. Also, AR may be superior to CW in terms of
afety and viable CD34 cell recovery. AR and CW
rovide greater stability of viable CD34 cells and
unctional HPC than direct thaw (infusion after thaw-
ng without AR or CW) where signiﬁcant loss of cell
iability and function is seen after 4 hours and may
ccur earlier as a result of exposure of the product to
0% DMSO. AR has no signiﬁcant adverse impact on
ransplant outcome and may offer a signiﬁcant beneﬁt
ver CW particularly in single unit transplants in
dults where cell dose is limited and cell recovery
ost-thaw is critical. Recommendations made in-
luded the use of AR in all settings were the post-
rocessing TNC dose is 3.5  107/kg. CW should
e considered if the TNC dose is 3.5  107/kg and
here is concern about DMSO toxicity (DMSO dose
1 g/kg) or major ABO incompatibility (30 mL
ncompatible RBC stroma).
ESSION 5. IMMUNE RECONSTITUTION FOLLOWING
CBT: GRAFT-VERSUS-LEUKEMIA, INFECTIOUS
OMPLICATIONS, AND ADOPTIVE IMMUNOTHERAPY
Review lecture. Dr. Mary Eapen reviewed the topic
f graft-versus-leukemia (GVL) effect after alloge-
eic transplantation for acute leukemia. She indi-
ated that allografts initiate immune responses which
re strongest when major HLA antigens of the donor
nd recipient are incompatible, and are weaker when
nvolving minor HLA antigens. A study by the
BMTR of 2,000 recipients of HLA-matched sib-
ing donor transplants for ALL, AML, or CML
CR1 or CP1) indicated that there was a lower
elapse rate after non-T-cell depleted BMT in pa-
ients with aGVHD, cGVHD or aGVHD and
GVHD. Further, the relapse rates correlated with
VHD severity. A GVL effect may also occur in the
bsence of GVHD following BMT as suggested by
he fact that there is a lower relapse rate after twin
ransplants when patients receive3 108 cells/kg. A
VL effect is also found when there is a donor/
ecipient sex mismatch, as indicated by a lower risk of
elapse in male recipients of female donors even if
hey do not develop GVHD. In unrelated donor
ransplantation, GVHD rates are higher, relapse
ates are lower but TRM is higher. Consequently,
he inﬂuence of GVHD on overall survival is the
alance of higher TRM and lower relapse rates.
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Summary of IUCBT Symposium1214Dr. Maria S. Albano discussed CMV infections in
ord blood transplantation and screening strategies
or cord blood (CB) donors. She indicated that donor
MV-antibody status is relevant for BMT donor se-
ection, but the strategy for screening CMV among
B donors is not clear. A positive test for antibody to
MV in an adult BM donor indicates active or latent
nfection, but a positive antibody test in a newborn
ay detect maternal antibody and is not necessarily
vidence of infection in the infant donor. A number of
tudies carried out at the New York Blood Center
ational Cord Blood Program indicated the follow-
ng: Regarding CB recipients for HSCT, the inci-
ence of post-transplant CMV infection was higher in
atients with pre-transplant CMV-antibody positive
est. CMV infection after CB transplantation was a
igniﬁcant cause of post-transplant morbidity and
ortality and CB donor-maternal CMV-antibody
ositive test (total and IgM) was not associated with
MV infection in the recipients. Regarding CB do-
ors: the incidence of CMV infection among CB
onors (saliva culture and CB-PCR) was low (0.12%).
aternal serology (total antibody and IgM) had a low
ositive predictive value for diagnosis of CMV infec-
ion in infant donors. Only 1/3 of infants with con-
rmed CMV infection had a CMV-IgM positive
other. This means that 2/3 of infants with conﬁrmed
nfection would be missed by IgM screening. Detec-
ion of CMV-DNA in CB by PCR is a good alterna-
ive to viral culture for screening among CB donors.
Dr. Jeffrey Miller discussed NK cells and KIR
ismatch in cord blood transplantation. He reviewed
he results of a study of the signiﬁcance of KIR ligand
KIR-L) mismatches in 243 patients with hematologic
alignancies who were transplanted with CB units.
here was no difference in grades II-IV or III-IV
GVHD rates based on KIR-L mismatch, there was a
rend to less relapse if KIR-L mismatch was present
but this was not statistically signiﬁcant), and there
as a slight increase in TRM if KIR-L mismatch was
resent. In double cord transplants, the investigators
ypothesized that NK cell alloreactivity may predict
he winning unit; their data suggested that NK cell
lloreactivity of unit 2 against the recipient predicts
ngraftment of unit 1. (Variables that did not predict
he winner were infusion order, mononuclear cell
ose, CD34 dose, CD3 dose and CFU-GM dose.) In
study of adoptive transfer of haploidentical NK cells,
9 patients with AML were treated with allogeneic
K cells which were infused on transplant day 0 and
hen expanded in vivo with IL-2 3/week  6 doses.
KIR-L mismatched donor correlated with achieving
ML CR (P  0.04). Conclusions were that NK
ells are important in transplantation; KIR reconsti-
ution after UCB transplant may predict the winner in
ouble CBT and provide a clinically important func-
ional advantage for NK cell alloreactivity in advanced peukemias. Also, UCB may provide a useful source of
ells for adoptive NK cell transfer.
Dr. Prakash Satwani discussed the optimal ex vivo
xpansion of cord blood natural killer (NK) cells, NK
ytotoxicity and NK receptor expression and the po-
ential for CB adoptive cellular immunotherapy. He
ointed out that UCBT is limited by the absence of
vailable donor effector cells (NK, CTL, LAK and
KT) for DLI for the treatment of hematological
elapse and/or PTLD. Remissions have been pro-
uced by DLI in patients with hematologic malignan-
ies in relapse. Also, donor-versus-recipient NK cell
lloreactivity reduced the risk of leukemia relapse in a
tudy of 57 AML patients at high risk of relapse, while
mproving engraftment and protecting against GVHD.
tudies in the authors’ laboratory indicated that ex
ivo expansion of CB with IL-2, IL-7, IL-12 and
nti-CD3 (AB/CY) for 7-10 days resulted in a signif-
cant increase in NK cells expressing C-lectin receptor
D94/NKG2D; an increase in NK cells (dim and
right) NK KAR KIR2DS4; a decrease in NK cell
CR NKp44dim subset; and a decrease in NK cell
CR NKp46dim subset. In summary, there is an in-
rease in NK cytotoxicity, an increase in LAK cyto-
oxicity, an increase in granzyme B expression, and a
ecrease in perforin expression.
Dr. Laurence Cooper discussed the differentiation of
aive cord blood T cells into CD19-speciﬁc cytolytic
ffectors for post-transplant adoptive immunotherapy.
ne can produce chimeric immunoreceptors which
ouple recognition domains with TCR-signaling do-
ains to redirect speciﬁcity of T cells to cell-surface
ntigens independent of MHC. The investigators de-
eloped chimeric antigen receptors (CARs) to redirect
he speciﬁcity of T cells for CD19, a B-lineage anti-
en, and expressed these transgenes in UCB-derived
cells. In vitro experiments using a chromium release
ssay of primary B-ALL cells demonstrated the effec-
iveness of the CD19-speciﬁc T cells and in vivo
xperiments indicated their value for adoptive immu-
otherapy. A second generation immunoreceptor was
eveloped termed CD19RCD28 to provide T-cell co-
timulation for CD19CD80	CD86	 targets; this
rovided improved T-cell persistence and efﬁcacy. A
ajor objective of the research is to assess the safety
nd feasibility of cellular immunotherapy following
CB transplant by administering ex vivo expanded
onor-derived T cells (genetically modiﬁed to express
CD19-speciﬁc chimeric immunoreceptor) into re-
earch participants with CD19 ALL after non-my-
loablative or ablative conditioning regimens.
ESSION 6. TRANSPLANTATION OF CHILDREN
Review lecture. Dr. Joanne Kurtzberg discussed
rogress in UCBT for inborn errors of metabolism.
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Summary of IUCBT Symposium 1215articular emphasis was placed on transplantation of
atients with the severe phenotype of Hurler syn-
rome (PMS I) and Krabbe disease, or globoid-cell
eukodystrophy. In Hurler patients, UCBT resulted in
urable engraftment, normalization of alpha-L-idu-
onidase levels and improvement in cognitive function
ith an overall survival of 85%. Krabbe disease is an
utosomal recessive disorder due to deﬁciency of the
ysosomal enzyme galactocerebrosidase, characterized
y failure of the process of myelination in the central
nd peripheral nervous systems, rapidly progressive
eurologic deterioration, and death. In the infantile
orm, symptoms appear before 6 months of age and
nclude irritability, dysphagia, progressive spasticity,
ental deterioration, blindness, deafness, seizures,
nd death, usually before 2 years of age.
Forty-two patients have been transplanted, 17 of
hich were neonatal transplants. Results indicated
hat surviving patients showed durable engraftment of
onor-derived hematopoietic cells with restoration of
ormal blood galactocerebrosidase levels. Infants who
nderwent transplantation before the development of
ymptoms showed progressive central myelination
nd continued gains in developmental skills, and most
ad age-appropriate cognitive function and receptive
anguage skills, but a few had mild-to-moderate delays
n expressive language and mild-to-severe delays in
ross motor function. Children who underwent trans-
lantation after the onset of symptoms had minimal
eurologic improvement. Conclusions were that UCB
ransplantation is uniquely suited for pediatric patients
ith genetic diseases, inborn errors of metabolism,
one marrow failure syndromes, hemoglobinopathies,
nd immunodeﬁciency diseases.
Dr. Mary Eapen discussed “Unrelated donor he-
atopoietic stem cell transplantation in children with
cute leukemia: risks and beneﬁts of umbilical cord
lood vs bone marrow.” A study compared the out-
ome of 492 unrelated BM and 508 CB transplants in
atients younger than 16 years of age having ALL or
ML. Median follow-up of survivors was 59 months
or BM and 45 months for CB transplants. Recipients
f matched CB transplants had signiﬁcantly lower
ransplant related mortality (TRM), treatment failure
nd overall mortality than recipients of matched BM;
ecipients of high cell dose CB mismatched at 1 locus
ad risks similar to recipients of matched BM. Recip-
ents of low cell dose CB mismatched at 1 locus and
B mismatched at 2 loci (any cell dose) had higher
isks of TRM, treatment failure and mortality than
atched BM recipients during the early post trans-
lant period. However, among those surviving the
arly period, subsequent risks were similar to matched
M recipients. The data support use of CB matched
r mismatched at 1 locus with a high cell dose for
hildren needing HSCT whether or not a matched
M donor is available; low cell dose or 2-loci mis- batched CB grafts may provide a reasonable alterna-
ive when a matched BM donor is not available or for
hose whose disease requires immediate transplanta-
ion.
Dr. Vanderson Rocha discussed outcomes after un-
elated cord blood transplantation in children with
cute lymphoblastic leukemia; An Eurocord-Netcord
urvey. Few data are available on the outcomes after
CBT in children with ALL. An analysis of results was
erformed on 361 UCB transplants in children with
LL receiving an UCBT from 01/1995 to 01/2005 in 99
ransplant centres in 24 countries, mostly in Europe.
he children received a single non-expanded CB unit
nd a myeloablative conditioning regimen, and the
ajority (67%) received CsAcorticoids as GVHD
rophylaxis. The median age was 6.5 years, median
ell dose infused was 4.1  107/kg and the median
ollow-up time was 22 months (3-96). The cord blood
as HLA identical (6/6) in 12% of the cases, 5/6 in
6%, 4/6 in 39% and 3/6 in 3%. Overall 2 year-LFS
as 36  3%. In a multivariate analysis, only CR1 or
R2 were associated with better LFS (HR  1.8; P 
.0001). A separate analysis was performed according
o the disease status. Results indicated that status of
he disease at transplant was a major risk factor for
utcomes. The most important risk factor associated
ith relapse incidence and LFS after UCBT for chil-
ren in CR2 was the duration of CR1 (ﬁrst relapse on
r off therapy). Conclusions were that UCBT should
e proposed as alternative source of allogeneic trans-
lantation for children with high risk ALL in an ear-
ier status of the disease for those children lacking an
LA identical donor.
ESSION 7. DEVELOPMENT OF A NATIONAL CORD
LOOD PROGRAM
Robert Baitty, representing the Health Resources
nd Services Administration (HRSA), discussed im-
lementation of the Stem Cell Therapeutic and Re-
earch Act of 2005. The aims of the Act are to increase
he number of unrelated donor transplants, to increase
he public inventory of high quality CBUs from di-
erse populations, and to increase the number of
BUs available for research. A target of 150,000 new
nits was set. Cord blood banks will be funded for 3
ears through 1-time 10-year contracts awarded com-
etitively; in addition, there will be annual competi-
ions for new cohorts of banks. A national cord blood
oordinating center (CBCC) will also be developed
nd its functions will include the facilitation of trans-
lants with cord blood, coordination of contingency
lanning with banks, coordination of inter-bank pro-
ciency testing programs and compilation of data on
BUs released for research. An Advisory Council will
e established which may make recommendations in
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Summary of IUCBT Symposium1216uch areas as targets for national cord blood inventory
nd adult registry (size and composition), research
riorities, CBU characteristics needed for good out-
ome and the criteria for choosing the best stem cell
ource. The Advisory Council may also make recom-
endations regarding program priorities, public and
rofessional education regarding donation, and regu-
atory policy including international harmonization of
egulation.
ESSION 8. CORD BLOOD CELL BIOLOGY, EX VIVO
XPANSION, REGENERATIVE MEDICINE
Review lecture. Dr. Hal Broxmeyer reviewed ex vivo
xpansion and homing of cord blood stem cells. He
ointed out that a disadvantage of CB units is the
imiting number of stem and progenitor cells present
n a single cord blood collection. Potential solutions to
his problem are the use of multiple cord blood units,
x vivo expansion of HSC/HPC, enhanced homing/
ngraftment capability HSC/HPC, and/or direct in-
ra-bone marrow injection. Clinical results with ex
ivo expanded cord blood cells are thus far not very
ncouraging. Numerous groups have used various
ethods of modulating intracellular signalling com-
onents, including the use of STAT3 which is a down-
tream signalling molecule for a number of cytokine-
eceptor interactions. Recent work indicates that
TAT3 is a positive regulator for the following: in
ivo numbers and cycling status of HPC; in vitro
esponsiveness of HPC to synergistic stimulation by
ombinations of cytokines; in vitro replating of CFU-
EMM and CFU-M colonies into secondary culture
lates; and competitive repopulating hematopoietic
tem cells. Further studies suggest that SDF-1/
XCL12 has the ability to enhance the replating ca-
acity of murine bone marrow CFU-GEMM and
FU-M in vitro, which are measures of some degree
f “self-renewal” capacity. Studies of the mechanisms
nvolved in the self renewal capability of embryonic
tem cells may provide important information regard-
ng the self renewal capability of HPC. Since hema-
opoietic stem cells do not engraft with absolute efﬁ-
iencies, enhancement of homing/engraftment of
SC should produce signiﬁcant beneﬁt. Studies of
nhibition of CD26 indicates that such inhibition en-
ances allogeneic donor cell homing and engraftment.
n conclusion, several approaches in addition to the
se of multiple cord blood units are being studied
egarding the problem of limiting numbers of HSC in
ingle cord blood collections: ex vivo expansion of
SC through use of cytokines, stromal cells, mesen-
hymal cells, dendritic cells, etc, and/or modulation of
ey intracellular signalling molecules involved in HSC
unctions, and enhanced homing/engraftment of HSC
tilizing receptor and/or microenvironmental manip-
lation. sDr. Colleen Delaney’s presentation was entitled
Culture of CD34 umbilical cord blood progenitors
ith Notch ligand results in enhanced and more rapid
uman engraftment in a preclinical NOD/SCID
ouse model.” Efforts by others to overcome the
roblem of small cell numbers in UCB grafts by ex
ivo expansion, primarily by culture with cytokines,
ave not met with success. The author’s experiments
emonstrated that culture of UCB progenitors with
he Notch ligand, Delta1, results in enhanced gener-
tion of NOD/SCID repopulating cells. The investi-
ators cultured CD34 UCB progenitors in the pres-
nce of a Notch ligand form consisting of the
xtracellular domain of Delta1 fused to the Fc domain
f human IgG1 (Delta 1ext-IgG) or control human IgG.
xperiments in which cord blood CD34 progenitor
ells were cultured for 17 days with immobilized
elta1ext-IgG or control resulted in a mean fold expan-
ion of CD34 cells of 230  53 for the Delta-
ultured cells versus 65  31 for the control cultured
ells (P  0.03). Further, Delta-cultured cells resulted
n more rapid human engraftment and signiﬁcantly
nhanced overall levels of human engraftment in a
OD/SCID mouse model. Also found was signiﬁ-
antly greater frequency of SCID repopulating cells
SRC) detected 3 and 9 weeks following transplanta-
ion from the Delta1ext-IgG cultured cells as compared
o control cultured or non-cultured cells. Finally, in
nticipation of clinical application, results were pre-
ented in which mice received infusion of Delta-cul-
ured cells, with and without non-cultured cells.
hese results importantly demonstrated contribution
o human engraftment from both the cultured and
on-cultured cells (dual chimerism) as well as in-
reased human engraftment in mice that received co-
nfusions of cultured and non-cultured cells compared to
ither unit alone. Conclusions were that culture
f CD34 cord blood progenitors in the presence of
elta1 results in a signiﬁcant increase in generation of
D34 cells that are capable of repopulating NOD/
CID mice with an enhanced rate and magnitude.
lso, Delta1-cultured cord blood progenitors, when
sed in a clinical setting, may provide rapidly engraft-
ng cells capable of abrogating the prolonged period of
eutropenia in patients undergoing UCBT.
Dr. Mary Laughlin discussed “Umbilical cord
lood derived CD133 cells: Homing capability in
asculogenesis and immunogenicity.” An allogeneic
ource, rather than autologous patient-derived cells,
ay be optimal for cellular therapeutics to enhance
asculogenesis in response to ischemia. The author’s
tudies have focused on selected CD133 UCB-de-
ived HSC not only to enrich this population but also
o delete immune and antigen presenting cells from a
ononuclear prep that may exert strong adverse im-
unologic effects in a patient with an intact immuneystem. Phase I clinical trials incorporate dose esca-
l
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Summary of IUCBT Symposium 1217ating CD133 autologous marrow-derived HSC for
atients with a totally occluded coronary artery not
menable to standard revascularization intervention.
D133 HSC are administered via coronary infusion
n the vessel providing collateral blood ﬂow. The
ntent is to proceed to allogeneic UCB pending results
f the autologous trial and further UCB pre-clinical
afety and efﬁcacy analyses. Thus far, intracoronary
njection of autologous selected BM CD133 within
he dose range of 1-2  106 in patients with chronic
oronary ischemia is safe; UCB derived CD133 cells
ecrete angiogenic factors at basal conditions; UCB
erived CD133 cells express MHC class I and II
urface receptors and evoke allogeneic T cell prolif-
ration in standard MLR; CD 133 HSC from UCB
re functional in vivo and mediate signiﬁcant im-
rovement in blood ﬂow in the NOD/SCID femoral
ascular injury model.
Dr. Dan Collins discussed isolation and character-
zation of umbilical cord blood-derived multipotent
tem cells arising from the adherent CD45/CD34
ell subset. He reported the identiﬁcation of stem cells
istinct from MSCs deriving from a plastic adherent
D45/CD34 population with the ability to estab-
ish stable, readily expandable clones with extensive
ulti-lineage potential. Differentiation protocols have
een developed to induce conversion of MLPCs to
dipocytes, osteocytes, chondrocytes, myocytes, neu-
al and glial cells, endothelial cells, lung epithelial cells tnd hepato-pancreatic precursor cells. The ability of
ndividual clonal cell lines to differentiate into each of
he described cell types demonstrates the potential to
erive tissue types consistent with all three germinal
ayers. Early studies with extra-cellular matrices sug-
est a potential utility of MLPC in tissue engineering
s well as a tool for target validation and toxicity
esting in pharmaceutical development.
Dr. Paul Szabolcs discussed immune reconstitution
fter cord blood transplantation. Infections within the
rst 3-6 months after UCBT remain the major cause
f morbidity and mortality. The authors have exten-
ively studied 150 children, all unrelated cord blood
ecipients. The guiding hypothesis is that the kinetics
nd quality of immune recovery within the ﬁrst 2
onths after transplant are directly related to inter-
ctions between the adoptively transferred T cells,
ost factors, and the presence or absence of latent viral
nfections. Results indicated that in lymphopenic
CBT recipients, even prior to myeloid engraftment,
xtensive T cell proliferation induces a gradual loss of
he naïve phenotype. This is accompanied by emerg-
ng activated T cells displaying a memory phenotype.
n patients at risk for reactivating viral infections T
ell maturation shifts towards acquisition of effector
ytotoxic proﬁle predominantly in CD8 T cells
Tc1). Identiﬁcation of asymptomatic patients with
ubclinical viral infections may lead to early interven-
ions to reduce morbidity and mortality due to OI.
